As of 2025-12-26, the EV/EBITDA ratio of Altimmune Inc (ALT) is -5.77. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Altimmune's latest enterprise value is 521.83 mil USD. Altimmune's TTM EBITDA according to its financial statements is -90.39 mil USD. Dividing these 2 quantities gives us the above Altimmune EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.3x - 15.3x | 15.3x |
| Forward P/E multiples | 22.2x - 43.5x | 32.8x |
| Fair Price | (13.72) - (9.35) | (14.90) |
| Upside | -444.7% - -335.0% | -474.5% |
| Date | EV/EBITDA |
| 2025-12-23 | -5.80 |
| 2025-12-22 | -6.03 |
| 2025-12-19 | -5.65 |
| 2025-12-18 | -7.46 |
| 2025-12-17 | -7.53 |
| 2025-12-16 | -7.43 |
| 2025-12-15 | -7.83 |
| 2025-12-12 | -7.81 |
| 2025-12-11 | -7.92 |
| 2025-12-10 | -8.07 |
| 2025-12-09 | -8.21 |
| 2025-12-08 | -8.35 |
| 2025-12-05 | -7.76 |
| 2025-12-04 | -7.88 |
| 2025-12-03 | -7.56 |
| 2025-12-02 | -7.01 |
| 2025-12-01 | -7.27 |
| 2025-11-28 | -7.80 |
| 2025-11-26 | -7.65 |
| 2025-11-25 | -7.61 |
| 2025-11-24 | -7.54 |
| 2025-11-21 | -7.09 |
| 2025-11-20 | -6.55 |
| 2025-11-19 | -6.74 |
| 2025-11-18 | -6.83 |
| 2025-11-17 | -6.11 |
| 2025-11-14 | -6.07 |
| 2025-11-13 | -5.90 |
| 2025-11-12 | -6.17 |
| 2025-11-11 | -6.25 |
| 2025-11-10 | -6.22 |
| 2025-11-07 | -5.98 |
| 2025-11-06 | -5.71 |
| 2025-11-05 | -5.41 |
| 2025-11-04 | -5.43 |
| 2025-11-03 | -5.74 |
| 2025-10-31 | -5.88 |
| 2025-10-30 | -5.92 |
| 2025-10-29 | -5.80 |
| 2025-10-28 | -5.90 |
| 2025-10-27 | -6.03 |
| 2025-10-24 | -5.73 |
| 2025-10-23 | -5.74 |
| 2025-10-22 | -5.65 |
| 2025-10-21 | -5.87 |
| 2025-10-20 | -5.80 |
| 2025-10-17 | -5.54 |
| 2025-10-16 | -5.63 |
| 2025-10-15 | -5.80 |
| 2025-10-14 | -5.76 |